Multiple sclerosis (MS) research addressed several challenges in 2014, including progressive MS. Despite advances in other forms of MS, there are no approved treatments for progressive MS because of the scarcity of reliable methods to test when, how, and why MS progresses. Nonetheless, post-hoc analyses of placebocontrolled trials1,2 suggest that a subset of patients with progressive MS might benefi t from immunedirected therapies, which are usually eff ective in the management of relapsing–remitting MS.
MS and related disorders: Looking for markers of phenotypes
TROIANO, Maria;
2015-01-01
Abstract
Multiple sclerosis (MS) research addressed several challenges in 2014, including progressive MS. Despite advances in other forms of MS, there are no approved treatments for progressive MS because of the scarcity of reliable methods to test when, how, and why MS progresses. Nonetheless, post-hoc analyses of placebocontrolled trials1,2 suggest that a subset of patients with progressive MS might benefi t from immunedirected therapies, which are usually eff ective in the management of relapsing–remitting MS.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
trojano2015 (2).pdf
non disponibili
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
385.42 kB
Formato
Adobe PDF
|
385.42 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
